Robert Pearce

Robert Pearce
T: +44 (0) 20 7246 0517
E: robert.pearce@alantra.com

Robert is director at Alantra.

He works alongside our Partners and Directors to deliver all types of deals including company acquisitions and disposals, management buy-outs (MBOs), fund raisings and strategic reviews, acting for private business owners, management teams, corporates and private equity.​

Robert has a particular focus on the Business Services sector. He is instrumental in the production of the CIWM & Alantra Waste Fast 50 and the Grocer Food & Drink Fast 50.

 

During his Accounting and Finance degree at Nottingham Business School, Robert undertook a placement year at Catalyst working as a junior analyst within the research department. On graduation, he spent a year working within his family business.

Robert has supported the delivery of a number of transactions including the £163m acquisition of Concept Life Sciences by Spectris plc; the management buy-out of YSC (2017), five acquisitions for Spain's SAICA, the most recent being the acquisition of Americk Packaging; the sales of CP Electronics and Texon; working with the shareholders of Powwownow on its sale to US-based PGi; and supporting Daelmans on the identification and acquisition of Fabulous Bakin’ Boys.

Outside of work Robert enjoys a host of country pursuits and is a keen competitive cyclist.

Alantra appoints experienced partner to head up its UK Real Estate & Hospitality team

Alantra has appointed Hoong Wey Woon as a Partner to head up its UK Real Estate & Hospitality team.  

Alantra advises Strong Roots on securing over €15.5m of investment

Alantra advises Strong Roots, one of the UK’s fastest-growing food companies, on securing over €15.5m of investment 

Alantra advises i2S on its sale to Gfi Informatique

Alantra advises Portuguese IT firm, i2S, on its sale to Gfi Informatique 

Alantra expands its technology sector team with two senior appointments

Alantra has expanded its Technology Media and Telecoms (TMT) sector team with two senior appointments. James Chapman-Andrews joins as Partner and Head of UK TMT and Simon Devonshire OBE, joins as Technology Industry Adviser.  

Alantra advises on sale of 3P Biopharmaceuticals to Keensight Capital

We advised Cinfa and the rest of the shareholders on the sale of 3P Biopharmaceuticals to Keensight Capital, a European growth private equity fund with deep expertise in healthcare.